KR20110036608A - 유방암 위험도 평가를 위한 유전적 변이 - Google Patents
유방암 위험도 평가를 위한 유전적 변이 Download PDFInfo
- Publication number
- KR20110036608A KR20110036608A KR1020117002889A KR20117002889A KR20110036608A KR 20110036608 A KR20110036608 A KR 20110036608A KR 1020117002889 A KR1020117002889 A KR 1020117002889A KR 20117002889 A KR20117002889 A KR 20117002889A KR 20110036608 A KR20110036608 A KR 20110036608A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- breast cancer
- markers
- individual
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 434
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 434
- 238000012502 risk assessment Methods 0.000 title claims description 20
- 230000007614 genetic variation Effects 0.000 title description 26
- 238000000034 method Methods 0.000 claims abstract description 253
- 230000002068 genetic effect Effects 0.000 claims abstract description 107
- 201000010099 disease Diseases 0.000 claims abstract description 100
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 100
- 238000011282 treatment Methods 0.000 claims abstract description 81
- 238000003745 diagnosis Methods 0.000 claims abstract description 26
- 230000004044 response Effects 0.000 claims abstract description 25
- 238000004393 prognosis Methods 0.000 claims abstract description 11
- 108020004414 DNA Proteins 0.000 claims description 630
- 108700028369 Alleles Proteins 0.000 claims description 365
- 102000054766 genetic haplotypes Human genes 0.000 claims description 216
- 150000007523 nucleic acids Chemical class 0.000 claims description 182
- 239000000523 sample Substances 0.000 claims description 174
- 108090000623 proteins and genes Proteins 0.000 claims description 165
- 239000003550 marker Substances 0.000 claims description 147
- 102000039446 nucleic acids Human genes 0.000 claims description 146
- 108020004707 nucleic acids Proteins 0.000 claims description 146
- 239000002773 nucleotide Substances 0.000 claims description 111
- 125000003729 nucleotide group Chemical group 0.000 claims description 111
- 206010028980 Neoplasm Diseases 0.000 claims description 79
- 238000003205 genotyping method Methods 0.000 claims description 74
- 230000035772 mutation Effects 0.000 claims description 61
- 230000035945 sensitivity Effects 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 45
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 39
- 108091034117 Oligonucleotide Proteins 0.000 claims description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 230000002829 reductive effect Effects 0.000 claims description 31
- 230000015654 memory Effects 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 102000036365 BRCA1 Human genes 0.000 claims description 23
- 230000000295 complement effect Effects 0.000 claims description 23
- 229940124597 therapeutic agent Drugs 0.000 claims description 23
- 108700020463 BRCA1 Proteins 0.000 claims description 22
- 101150072950 BRCA1 gene Proteins 0.000 claims description 22
- 101150008921 Brca2 gene Proteins 0.000 claims description 22
- 102000052609 BRCA2 Human genes 0.000 claims description 21
- 108700020462 BRCA2 Proteins 0.000 claims description 21
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 20
- 239000002751 oligonucleotide probe Substances 0.000 claims description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 16
- 239000013068 control sample Substances 0.000 claims description 14
- 238000012544 monitoring process Methods 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 9
- 239000012472 biological sample Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 230000035699 permeability Effects 0.000 claims description 6
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 5
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004224 protection Effects 0.000 claims description 4
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 3
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 3
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 claims description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 238000004590 computer program Methods 0.000 claims 1
- 238000007726 management method Methods 0.000 abstract description 7
- 241000282414 Homo sapiens Species 0.000 description 592
- 108090000765 processed proteins & peptides Proteins 0.000 description 77
- 102000004196 processed proteins & peptides Human genes 0.000 description 76
- 229920001184 polypeptide Polymers 0.000 description 75
- 230000014509 gene expression Effects 0.000 description 64
- 102000004169 proteins and genes Human genes 0.000 description 52
- 238000012360 testing method Methods 0.000 description 48
- 201000011510 cancer Diseases 0.000 description 43
- 238000001514 detection method Methods 0.000 description 42
- 238000004458 analytical method Methods 0.000 description 37
- 210000000349 chromosome Anatomy 0.000 description 37
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 description 28
- 238000003556 assay Methods 0.000 description 27
- 238000009396 hybridization Methods 0.000 description 27
- 238000012216 screening Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 108020004999 messenger RNA Proteins 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 101000890757 Homo sapiens FH1/FH2 domain-containing protein 3 Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 102100040129 FH1/FH2 domain-containing protein 3 Human genes 0.000 description 22
- 101001132307 Homo sapiens DNA repair protein RAD51 homolog 2 Proteins 0.000 description 22
- 102100040244 Trinucleotide repeat-containing gene 6B protein Human genes 0.000 description 22
- 239000000969 carrier Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 22
- 238000003860 storage Methods 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- 101000633968 Homo sapiens Tubby protein homolog Proteins 0.000 description 20
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 20
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 19
- 239000013615 primer Substances 0.000 description 19
- 238000001959 radiotherapy Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 102100027287 Serpin H1 Human genes 0.000 description 18
- 102100029249 Tubby protein homolog Human genes 0.000 description 18
- 230000008859 change Effects 0.000 description 18
- 230000006798 recombination Effects 0.000 description 18
- 238000005215 recombination Methods 0.000 description 18
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 17
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 16
- 230000000692 anti-sense effect Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 230000009368 gene silencing by RNA Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000003623 enhancer Substances 0.000 description 15
- 102000015694 estrogen receptors Human genes 0.000 description 15
- 108010038795 estrogen receptors Proteins 0.000 description 15
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 description 14
- 108091092878 Microsatellite Proteins 0.000 description 14
- 238000009607 mammography Methods 0.000 description 14
- 102000003998 progesterone receptors Human genes 0.000 description 14
- 108090000468 progesterone receptors Proteins 0.000 description 14
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 13
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 230000000875 corresponding effect Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000002853 nucleic acid probe Substances 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000004891 communication Methods 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 229960001603 tamoxifen Drugs 0.000 description 10
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 8
- 102220362489 c.10C>A Human genes 0.000 description 8
- 102220371036 c.22C>A Human genes 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000002987 primer (paints) Substances 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102200024044 rs1555523872 Human genes 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000000074 antisense oligonucleotide Substances 0.000 description 7
- 238000012230 antisense oligonucleotides Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 7
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 description 6
- 101710018890 RAD51B Proteins 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 230000002759 chromosomal effect Effects 0.000 description 6
- 210000003917 human chromosome Anatomy 0.000 description 6
- 239000002679 microRNA Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 5
- 102000004533 Endonucleases Human genes 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000030776 invasive breast carcinoma Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 108091070501 miRNA Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 208000033640 Hereditary breast cancer Diseases 0.000 description 4
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000011226 adjuvant chemotherapy Methods 0.000 description 4
- 238000012098 association analyses Methods 0.000 description 4
- 201000005389 breast carcinoma in situ Diseases 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 230000009395 genetic defect Effects 0.000 description 4
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 201000011059 lobular neoplasia Diseases 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000012775 microarray technology Methods 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009862 primary prevention Effects 0.000 description 4
- 229960004622 raloxifene Drugs 0.000 description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000000528 statistical test Methods 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 108700010154 BRCA2 Genes Proteins 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000611192 Homo sapiens Trinucleotide repeat-containing gene 6B protein Proteins 0.000 description 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 3
- 108091092919 Minisatellite Proteins 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 101710087261 Trinucleotide repeat-containing gene 6B protein Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003886 aromatase inhibitor Substances 0.000 description 3
- 229940046844 aromatase inhibitors Drugs 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 239000012627 chemopreventive agent Substances 0.000 description 3
- 229940124443 chemopreventive agent Drugs 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 3
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 238000012252 genetic analysis Methods 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000005055 memory storage Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000006855 networking Effects 0.000 description 3
- 238000002966 oligonucleotide array Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000013439 planning Methods 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000009863 secondary prevention Effects 0.000 description 3
- 229940126586 small molecule drug Drugs 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000011277 treatment modality Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 241000722946 Acanthocybium solandri Species 0.000 description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 2
- 108700040618 BRCA1 Genes Proteins 0.000 description 2
- 101150064168 CHEK2 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101100220617 Homo sapiens CHEK2 gene Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 230000003632 chemoprophylactic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000013058 risk prediction model Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- CDFKCKUONRRKJD-UHFFFAOYSA-N 1-(3-chlorophenoxy)-3-[2-[[3-(3-chlorophenoxy)-2-hydroxypropyl]amino]ethylamino]propan-2-ol;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.C=1C=CC(Cl)=CC=1OCC(O)CNCCNCC(O)COC1=CC=CC(Cl)=C1 CDFKCKUONRRKJD-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 102100024420 39S ribosomal protein S30, mitochondrial Human genes 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010006253 Breast fibrosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000018672 Dilatation Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000689854 Homo sapiens 39S ribosomal protein S30, mitochondrial Proteins 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101000984710 Homo sapiens Lymphocyte-specific protein 1 Proteins 0.000 description 1
- 101100351019 Homo sapiens PAX5 gene Proteins 0.000 description 1
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 description 1
- 101100099892 Homo sapiens TNRC6B gene Proteins 0.000 description 1
- 101000679548 Homo sapiens TOX high mobility group box family member 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 238000003657 Likelihood-ratio test Methods 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 101150017484 PAX5 gene Proteins 0.000 description 1
- 235000011464 Pachycereus pringlei Nutrition 0.000 description 1
- 240000006939 Pachycereus weberi Species 0.000 description 1
- 235000011466 Pachycereus weberi Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000033722 Rare malignant breast tumor Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100022608 TOX high mobility group box family member 3 Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101150003160 X gene Proteins 0.000 description 1
- DUDJTRNGXIUJEB-UHFFFAOYSA-N [N].NCC(O)=O Chemical group [N].NCC(O)=O DUDJTRNGXIUJEB-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007727 cost benefit analysis Methods 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 101150097231 eg gene Proteins 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 101150046383 gene 5 gene Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- RVRCFVVLDHTFFA-UHFFFAOYSA-N heptasodium;tungsten;nonatriacontahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[W].[W].[W].[W].[W].[W].[W].[W].[W].[W].[W] RVRCFVVLDHTFFA-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011454 long-term hormonal therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000016044 mixed lobular and ductal breast carcinoma Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000000177 oncogenetic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 101150039612 rpsK gene Proteins 0.000 description 1
- 102210007986 rs12159200 Human genes 0.000 description 1
- 102210050605 rs17001974 Human genes 0.000 description 1
- 102220381284 rs17001977 Human genes 0.000 description 1
- 102220438908 rs17002069 Human genes 0.000 description 1
- 102200081254 rs28997576 Human genes 0.000 description 1
- 102210056307 rs9607721 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Library & Information Science (AREA)
- Computing Systems (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8746 | 2008-07-07 | ||
| IS8746 | 2008-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110036608A true KR20110036608A (ko) | 2011-04-07 |
Family
ID=41110719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117002889A Ceased KR20110036608A (ko) | 2008-07-07 | 2009-07-03 | 유방암 위험도 평가를 위한 유전적 변이 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8951735B2 (enExample) |
| EP (1) | EP2313525A2 (enExample) |
| JP (1) | JP2011527565A (enExample) |
| KR (1) | KR20110036608A (enExample) |
| CN (1) | CN102144036B (enExample) |
| AU (1) | AU2009269542A1 (enExample) |
| CA (1) | CA2729934A1 (enExample) |
| IL (1) | IL210504A0 (enExample) |
| NZ (1) | NZ590833A (enExample) |
| WO (1) | WO2010004591A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014119914A1 (ko) * | 2013-02-01 | 2014-08-07 | 에스케이텔레콤 주식회사 | 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011095999A1 (en) * | 2010-02-05 | 2011-08-11 | Decode Genetics Ehf | Genetic variants for predicting risk of breast cancer |
| EP2721180A4 (en) * | 2011-06-16 | 2015-09-02 | Decode Genetics Ehf | GENETIC VARIANTS FOR PREDICTING THE RISK OF BREAST CANCER |
| CN102643905B (zh) * | 2012-04-01 | 2014-06-11 | 周宏灏 | 焦磷酸测序法检测他莫昔芬个体化用药基因多态性的试剂盒及方法 |
| KR101770962B1 (ko) * | 2013-02-01 | 2017-08-24 | 에스케이텔레콤 주식회사 | 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치 |
| WO2014145705A2 (en) | 2013-03-15 | 2014-09-18 | Battelle Memorial Institute | Progression analytics system |
| CN103981273B (zh) * | 2014-05-30 | 2017-01-18 | 复旦大学附属肿瘤医院 | 一组评估乳腺癌风险的突变基因群及其检测试剂盒 |
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| CN105069322B (zh) * | 2015-07-24 | 2018-01-12 | 上海尔云信息科技有限公司 | 疾病易感风险预测装置 |
| CN109074426B (zh) | 2016-02-12 | 2022-07-26 | 瑞泽恩制药公司 | 用于检测异常核型的方法和系统 |
| CN105586427B (zh) * | 2016-03-10 | 2020-06-19 | 厦门艾德生物医药科技股份有限公司 | 检测人类brca1和brca2基因突变的引物、试剂盒及方法 |
| US11332530B2 (en) | 2016-09-23 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| CN106676169B (zh) * | 2016-11-15 | 2021-01-12 | 上海派森诺医学检验所有限公司 | 一种用于乳腺癌易感基因brca1和brca2突变检测的杂交捕获试剂盒及其方法 |
| CA3051488A1 (en) * | 2017-01-24 | 2018-08-02 | Genetic Technologies Limited | Improved methods for assessing risk of developing breast cancer |
| CN107341347A (zh) * | 2017-06-27 | 2017-11-10 | 天方创新（北京）信息技术有限公司 | 基于评分模型对乳腺癌进行风险评分的方法及装置 |
| EP3814521A4 (en) * | 2018-06-29 | 2022-07-27 | The Jackson Laboratory | SPLICING VARIANTS FOR BREAST CANCER |
| CN108676890B (zh) * | 2018-07-12 | 2022-01-28 | 吉林大学 | 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统 |
| US20230170045A1 (en) * | 2020-04-20 | 2023-06-01 | Myriad Genetics, Inc. | Comprehensive polygenic risk prediction for breast cancer |
| WO2024085660A1 (ko) * | 2022-10-18 | 2024-04-25 | 제노플랜 인크 | 질병 발생 위험도 예측 장치 및 방법 |
| WO2024148280A1 (en) | 2023-01-06 | 2024-07-11 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US6287850B1 (en) | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| EP0695941B1 (en) | 1994-06-08 | 2002-07-31 | Affymetrix, Inc. | Method and apparatus for packaging a chip |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| EP2369007B1 (en) | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| US20040009481A1 (en) * | 2001-06-11 | 2004-01-15 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| DE10228081A1 (de) * | 2002-06-18 | 2004-01-08 | InViTek Gesellschaft für Biotechnik & Biodesign mbH | Verfahren zum Nachweis einer gesteigerten Tumorsuszeptibilität |
| KR100763902B1 (ko) * | 2004-02-20 | 2007-10-05 | 삼성전자주식회사 | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 |
| WO2006063285A2 (en) * | 2004-12-10 | 2006-06-15 | Sequenom, Inc. | Methods for identifying risk of breast cancer or prostate cancer and treatments thereof |
| CN101037690B (zh) * | 2006-03-16 | 2011-07-20 | 国家人口计生委科学技术研究所 | 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体 |
| EP2089548A1 (en) * | 2006-10-27 | 2009-08-19 | Decode Genetics EHF | Cancer susceptibility variants on chr8q24.21 |
| CN101874120B (zh) | 2007-03-26 | 2015-01-14 | 解码遗传学私营有限责任公司 | 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型 |
| EP2164984A2 (en) | 2007-05-25 | 2010-03-24 | Decode Genetics EHF. | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
-
2009
- 2009-07-03 AU AU2009269542A patent/AU2009269542A1/en not_active Abandoned
- 2009-07-03 JP JP2011517318A patent/JP2011527565A/ja active Pending
- 2009-07-03 KR KR1020117002889A patent/KR20110036608A/ko not_active Ceased
- 2009-07-03 EP EP09787620A patent/EP2313525A2/en not_active Withdrawn
- 2009-07-03 WO PCT/IS2009/000008 patent/WO2010004591A2/en not_active Ceased
- 2009-07-03 CA CA2729934A patent/CA2729934A1/en not_active Abandoned
- 2009-07-03 CN CN200980134453.0A patent/CN102144036B/zh not_active Expired - Fee Related
- 2009-07-03 NZ NZ590833A patent/NZ590833A/xx not_active IP Right Cessation
- 2009-07-03 US US13/002,619 patent/US8951735B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 IL IL210504A patent/IL210504A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014119914A1 (ko) * | 2013-02-01 | 2014-08-07 | 에스케이텔레콤 주식회사 | 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL210504A0 (en) | 2011-03-31 |
| EP2313525A2 (en) | 2011-04-27 |
| AU2009269542A1 (en) | 2010-01-14 |
| US20110294673A1 (en) | 2011-12-01 |
| WO2010004591A2 (en) | 2010-01-14 |
| JP2011527565A (ja) | 2011-11-04 |
| WO2010004591A3 (en) | 2010-03-18 |
| CA2729934A1 (en) | 2010-01-14 |
| CN102144036A (zh) | 2011-08-03 |
| CN102144036B (zh) | 2014-07-16 |
| NZ590833A (en) | 2013-01-25 |
| US8951735B2 (en) | 2015-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250041457A1 (en) | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear | |
| CN101874120B (zh) | 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型 | |
| KR101571523B1 (ko) | 심혈관 질환과 연관된 유전적 감수성 변이 | |
| KR101708544B1 (ko) | 세포 증식 질환을 분석하기 위한 방법 및 핵산 | |
| KR20110036608A (ko) | 유방암 위험도 평가를 위한 유전적 변이 | |
| CA2566256C (en) | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | |
| KR102046668B1 (ko) | 암 대상자의 예후를 결정하기 위한 방법 및 핵산 | |
| KR102149483B1 (ko) | 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도 | |
| CN101641451A (zh) | chr8q24.21上的癌症易感性变体 | |
| US20090305284A1 (en) | Methods for Identifying Risk of Breast Cancer and Treatments Thereof | |
| KR102481305B1 (ko) | 유전자에 기반한 염증성 장 질환의 진단 | |
| KR20170086027A (ko) | 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법 | |
| KR20180049093A (ko) | 신규한 바이오마커 및 암의 치료 방법 | |
| WO2006022629A1 (en) | Methods of identifying risk of type ii diabetes and treatments thereof | |
| KR20090087486A (ko) | 타입 ２ 당뇨병의 유전적 감수성 변이 | |
| CN101631876A (zh) | 2型糖尿病的遗传易感性变体 | |
| CN1704478A (zh) | 评估急性髓性白血病患者的方法 | |
| TW202227102A (zh) | 治療脂肪肝病之方法 | |
| EP1729930A2 (en) | Methods for identifying risk of osteoarthritis and treatments thereof | |
| WO2006022636A1 (en) | Methods for identifying risk of type ii diabetes and treatments thereof | |
| WO2006022638A1 (en) | Methods for identifying risk of type ii diabetes and treatments thereof | |
| IL179831A (en) | In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders | |
| AU2017209307A1 (en) | Compositions and methods for screening and identifying clinically aggressive prostate cancer | |
| KR20220118096A (ko) | 항암제에 대한 내성 진단용 조성물 | |
| EA048246B1 (ru) | Способ лечения жировой болезни печени |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20110207 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20140625 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20151008 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20151217 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20151008 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |